Every Form 4 that Serina Therapeutics (SER) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SER and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SER filings page.
Serina Therapeutics, Inc. reported that director Simon Farrell received a grant of stock options covering 30,500 shares of common stock. The options have an exercise price of $2.1700 per share, expire on 2036-07-22, and vest in substantially equal yearly installments over three years beginning on the first anniversary of the grant date, subject to his continued service. Following this grant, Farrell holds 30,500 stock options directly.
Serina Therapeutics, Inc. director Stephen K. Brannan reported an open-market purchase of common stock. On July 7, 2026, he bought 1,000 shares of Serina Therapeutics common stock at a price of $2.03 per share. After this transaction, he directly holds 1,000 shares.
Serina Therapeutics director Jay Venkatesan reported multiple equity-related transactions. A trust associated with him, The Jay Venkatesan Legacy Trust, acquired 224,152 shares of common stock on mandatory conversion of 96,525 shares of Series A Convertible Preferred Stock at an adjusted conversion price of $2.25 per share, including 1,930 shares issued for accrued dividends. Following this, the trust held 231,705 common shares indirectly. Venkatesan also received a grant of 15,250 stock options with a $1.98 exercise price expiring in 2036, which will vest around the next annual meeting, and he bought 589 common shares in an open‑market transaction at $1.78 per share. A footnote notes an earlier administrative error that misclassified certain holdings between direct and indirect ownership.
Serina Therapeutics director Gregory Bailey reported a series of stock acquisitions and conversions tied to prior financing agreements and equity awards. On June 17, 2026, 762,548 shares of Series A Convertible Preferred Stock were mandatorily converted into 1,755,555 shares of common stock, plus 15,250 additional shares issued as accrued dividends, after stockholders approved the conversion terms.
Separate transactions show common stock issued upon automatic conversion of Pre-Funded Warrants originally purchased at $2.2499 per warrant under a March 17, 2026 Securities Purchase Agreement, following stockholder approval obtained on June 17, 2026. Bailey also received 3,333,333 redeemable warrants with a $5.00 exercise price and 15,250 stock options with a $1.98 exercise price as additional derivative awards.
Serina Therapeutics, Inc. director Stephen K. Brannan received a grant of stock options covering 15,250 shares of common stock. The options have an exercise price of $1.98 per share and expire on June 17, 2036. They vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the June 17, 2026 grant date, subject to his continued service with the company. Following this grant, he holds 15,250 stock options, reflecting a routine compensation-related award rather than an open-market trade.
Serina Therapeutics, Inc. reported that director Karen J. Wilson received a grant of stock options covering 15,250 shares of common stock at an exercise price of $1.98 per share. These options expire on June 17, 2036 and relate to 15,250 underlying common shares.
According to the footnotes, the options will vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to her continued service. A separate row shows she beneficially owns 30,100 common shares, which is an updated holding and not a new transaction.
Serina Therapeutics, Inc. director Marshall Richard Peter reported receiving a grant of stock options covering 15,250 shares of common stock. The options have an exercise price of $1.98 per share and expire on June 17, 2036.
According to the filing, the options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to his continued service with the company. Following this grant, he holds 15,250 stock options directly from this award.
Serina Therapeutics director Karen J. Wilson bought additional common stock in two recent open-market purchases. She acquired 5,100 shares on June 11, 2026 at a weighted average price of $1.745 per share and 5,000 shares on June 12, 2026 at a weighted average price of $1.77 per share. After these transactions, she directly owns 10,100 shares of Serina Therapeutics common stock. The filing notes that each day’s price reflects multiple trades within narrow ranges around the reported averages.
Serina Therapeutics, Inc. reported that Chief Executive Officer Steven A. Ledger acquired 10,100 shares of common stock as a grant/award on May 26, 2026. The award is recorded at $1.93 per share, and his directly held common stock after this transaction totals 10,100 shares.
Serina Therapeutics, Inc. reported that SVP, CMC & Formulation Tenjarla Srini received a grant of stock options covering 85,558 shares of common stock. The options have an exercise price of $1.89 per share and expire on May 21, 2036.
According to the vesting terms, 12/48ths of the options vest 12 months after the vesting commencement date, and 1/48th vests monthly thereafter until fully vested. Following this grant, Srini holds 85,558 derivative securities directly, reflecting a routine compensation-related award rather than an open-market trade.
Serina Therapeutics Chief Executive Officer Steven A. Ledger received a grant of stock options for 380,825 shares of Common Stock at an exercise price of $1.89 per share. These options expire on May 21, 2036 and vest over four years, with 12/48ths vesting after 12 months and the remainder vesting in equal monthly installments.
Serina Therapeutics, Inc. reported that Chief Financial Officer Gregory S. Curhan received a compensation grant of stock options covering 123,019 shares of common stock at an exercise price of $1.89 per share. The options vest over four years, with 12/48ths vesting one year after the Vesting Commencement Date and 1/48th each month thereafter, and expire on May 21, 2036. Following this award, Curhan holds stock options for 123,019 underlying shares directly.
Serina Therapeutics, Inc. Chief Scientific Officer Moreadith Randall received a grant of stock options covering 85,558 shares of common stock. The options have an exercise price of $1.89 per share and expire on May 21, 2036.
These options were granted at no upfront cost and are held directly. According to the vesting terms, 12/48ths of the options vest twelve months after the vesting commencement date, with an additional 1/48th vesting each month thereafter until fully vested.
Serina Therapeutics director Karen J. Wilson reported open-market purchases of Serina Therapeutics, Inc. common stock. She bought 10,000 shares at a price of $1.77 per share on May 21, 2026 and 10,000 shares at $1.93 per share on May 22, 2026.
After these transactions, Wilson directly owns 20,000 common shares. Footnotes state each reported price is a weighted average for multiple trades, with actual purchase prices ranging from $1.76 to $1.79 and from $1.90 to $1.95 per share.
Serina Therapeutics director Marshall Richard Peter bought 12,183 shares of common stock in an open-market transaction. The purchase occurred on May 19, 2026 at a weighted average price of $1.65 per share, with trade prices ranging from $1.59 to $1.73. Following this transaction, he directly holds 12,183 shares of Serina Therapeutics common stock.
Serina Therapeutics director Bailey Gregory acquired additional common stock through a share award. On March 31, 2026, Gregory received 59,667 shares of Serina Therapeutics common stock at $1.94 per share in a grant classified as a “grant, award, or other acquisition.”
According to a footnote, these shares were issued as payment of accrued dividends on the reporting individual’s Series A Convertible Preferred Stock issued on April 8, 2025. Following this transaction, Gregory directly holds 126,910 shares of Serina Therapeutics common stock.
Serina Therapeutics, Inc. director Venkatesan Jay reported an acquisition of 7,553 shares of common stock. These shares were issued at $1.94 per share as a grant classified as a “grant, award, or other acquisition.”
According to a footnote, the common shares were issued as payment of accrued dividends on the reporting individual’s A Convertible Preferred Stock issued on April 8, 2025. Following this non-cash dividend payment in stock, Jay directly holds 7,553 common shares.
Serina Therapeutics Chief Scientific Officer exercises and sells options-linked shares. On March 23, 2026, Randall Moreadith exercised stock options for 6,500 shares of common stock at an exercise price of $0.06 per share and then sold the same 6,500 shares in open-market transactions at a weighted average price of $2.8566 per share, with individual sale prices ranging from $2.68 to $3.03. This exercise-and-sell pattern represents a routine liquidity transaction rather than an open-market purchase.
Serina Therapeutics, Inc. Chief Scientific Officer Randall Moreadith exercised stock options for 39,000 shares of common stock at $0.06 per share and immediately sold all 39,000 shares at $2.50 per share in an open-market transaction.
The filing shows this was an exercise-and-sell event, with the reported common stock holdings reduced to 0 shares directly after the sale. The stock options involved were fully vested before exercise.
Serina Therapeutics, Inc. reported an insider equity award to its Chief Scientific Officer, Randall Moreadith. On February 3, 2026, he received a grant of 69,000 stock options with an exercise price of $2.76 per share, each option linked to one share of common stock.
The options were granted at no cost to him and are held as direct ownership. According to the vesting terms, 12/48ths of the options vest 12 months after the vesting commencement date, and the remaining portion vests in equal monthly installments of 1/48th until fully vested. After this grant, he beneficially owns 69,000 derivative securities in the form of these options.
Serina Therapeutics, Inc. reported that senior vice president of CMC & Formulation Tenjarla Srini received a grant of stock options on common stock. The award covers 69,000 stock options with an exercise price of $2.76 per share, dated February 3, 2026, held as direct ownership.
These options vest over time: 12/48ths of the shares vest twelve months after the vesting commencement date, and the remaining 1/48th vests on the same calendar day of each following month until fully vested. Following this grant, Srini beneficially owns 69,000 derivative securities in the form of these options.
Serina Therapeutics, Inc. reported that director Simba Gill received a grant of stock options. On 02/03/2026, he was awarded an option to acquire 92,000 shares of common stock at an exercise price of $2.76 per share, expiring on 02/03/2036.
According to the vesting terms, 12/48ths of the option shares vest twelve months after the vesting commencement date, with the remaining shares vesting in equal 1/48th monthly installments until fully vested, unless the option is earlier terminated under the option agreement.
Serina Therapeutics granted Chief Executive Officer and director Steven A. Ledger a stock option covering 230,100 shares of common stock at an exercise price of $2.76 per share. The option expires on 02/03/2036 and was awarded at a cost of $0 to the recipient.
According to the vesting terms, 12/48ths of the shares vest twelve months after the vesting commencement date, with 1/48th of the shares vesting monthly thereafter until fully vested. Following this grant, Ledger directly holds derivative securities representing 230,100 underlying shares.
Serina Therapeutics, Inc.'s Chief Scientific Officer, Randall Moreadith, reported an option exercise and share sale. On February 2, 2026, he exercised stock options for 6,500 shares of common stock at an exercise price of $0.06 per share and acquired these shares directly.
That same day, he sold 6,500 shares of common stock in a market transaction at a weighted average price of $3.0277 per share, with actual sale prices ranging from $3.00 to $3.05. After the sale, he reported owning 0 shares of common stock from this lot and 313,186 stock options that are fully vested.
Serina Therapeutics Chief Scientific Officer exercises options and sells shares. On January 28, 2026, Randall Moreadith exercised a stock option for 6,500 shares of common stock at an exercise price of $0.06 per share.
That same day he sold 6,500 common shares at a weighted average price of $3.567 per share, with individual sale prices ranging from $3.55 to $3.59, leaving 0 common shares directly owned after the sale and 319,686 stock options beneficially owned.
Serina Therapeutics, Inc. Chief Scientific Officer Randall Moreadith reported an option exercise and share sale. On January 22, 2026, he exercised a stock option for 2,500 shares of common stock at an exercise price of $0.06 per share, converting a stock option (right to buy) into common stock. That same day, he sold 2,500 shares of common stock in an open market transaction at a price of $2.95 per share, leaving him with 0 shares of common stock directly held after the sale.
Following these transactions, Moreadith continued to hold 326,186 stock options directly, according to the filing. A footnote states that the stock options involved are fully vested, meaning they were already earned and exercisable at the time of the transaction.
Serina Therapeutics Chief Scientific Officer trading update: On January 20 and 21, 2026, Chief Scientific Officer Randall Moreadith exercised stock options for a total of 4,000 shares of common stock at an exercise price of $0.06 per share and sold the same 4,000 shares in open-market transactions. The sales were reported at prices of $3.07 and $3.00 per share, leaving 0 shares of common stock directly owned after these transactions. Following the option exercises, he continued to hold 328,686 stock options with an exercise price of $0.06, which the filing states are fully vested.
Serina Therapeutics, Inc. Chief Scientific Officer Randall Moreadith reported option exercises and stock sales in mid-January 2026. On January 13, 2026, he exercised stock options to acquire 5,416 shares of Serina common stock at an exercise price of $0.06 per share, then sold 5,416 shares at a weighted average price of $2.50 per share. On January 14, 2026, he exercised options for an additional 1,084 shares at $0.06 per share and sold 1,084 shares at a weighted average price of $2.5031 per share, leaving him with no directly held common stock after these transactions.
Following the reported transactions, Moreadith beneficially owned 332,686 stock options with an exercise price of $0.06 per share, expiring on May 6, 2031, and the filing notes that these stock options are fully vested.
Serina Therapeutics Chief Scientific Officer reports option exercise and sale of shares. On 01/08/2026, Randall Moreadith exercised stock options for 13,000 shares of Serina Therapeutics, Inc. common stock at an exercise price of $0.06 per share. On the same date, he sold 13,000 shares of common stock at a weighted average price of $2.6887 per share, with individual sale prices ranging from $2.85 to $2.60. Following these transactions, he reported owning no shares of common stock directly and 339,186 stock options, which the filing states are fully vested.
Serina Therapeutics reported an insider equity transaction by its Chief Scientific Officer, Randall Moreadith. On 12/23/2025, he exercised a stock option to buy 4,100 shares of common stock at an exercise price of $0.06 per share, then sold 4,100 shares of common stock at a sale price of $2.6 per share on the same date.
After this transaction, he continued to hold 352,186 stock options directly, each with an exercise price of $0.06 and an expiration date of 05/06/2031. The filing notes that these stock options are fully vested, meaning they are already earned and exercisable under the plan terms.
Serina Therapeutics, Inc. reported an insider transaction by its Chief Scientific Officer on 12/22/2025. The officer exercised a stock option to buy 5,673 shares of common stock at an exercise price of $0.06 per share and on the same day sold 5,673 shares at a weighted average price of $2.6737 per share. The sale price reflects multiple trades at prices ranging from $2.705 to $2.66. After these transactions, the reporting person held 0 shares of common stock directly but continued to hold 356,286 stock options, which are fully vested and exercisable for common stock until 05/06/2031.
Serina Therapeutics Chief Scientific Officer Randall Moreadith exercised stock options and immediately sold the resulting shares. On 12/16/2025, he exercised 3,227 stock options at an exercise price of $0.06 per share, receiving the same number of common shares. He then sold all 3,227 shares at a weighted average price of $2.9631 per share in multiple trades between $3.00 and $2.96, leaving him with 0 shares of common stock held directly.
Following this transaction, Moreadith continues to hold 361,959 stock options with an exercise price of $0.06 per share, which are fully vested and expire on 05/06/2031.
Serina Therapeutics, Inc.'s Chief Scientific Officer, Randall Moreadith, reported insider equity transactions dated 12/12/2025. He acquired 1,700 shares of common stock at $0.06 per share and, on the same date, sold 1,700 shares at a weighted average price of $3.2597, with sale prices ranging from $3.25 to $3.275. After these transactions, he directly held 0 shares of common stock.
The report also lists a stock option (right to buy) with an exercise price of $0.06 per share, covering 1,700 underlying shares in this transaction and expiring on 05/06/2031. Following the activity, 365,186 derivative securities (stock options) are shown as beneficially owned, and the stock options are described as fully vested.
Serina Therapeutics, Inc. insider trading report: the company’s Chief Scientific Officer exercised a stock option for 3,555 shares of common stock at an exercise price of $0.06 per share on 12/11/2025 and sold the same 3,555 shares the same day. The reported sale had a weighted average price of $3.2404 per share, based on multiple trades between $3.20 and $3.35. After these transactions, the reporting person held no shares of common stock directly but continued to hold 366,886 stock options that remain fully vested.
Serina Therapeutics, Inc. reported insider stock transactions by its Chief Scientific Officer on a Form 4. On December 9, 2025, the officer exercised stock options to buy 600 shares of common stock at an exercise price of $0.06 per share, then sold 600 shares at a weighted average price of $3.3133 per share, with individual sale prices ranging from $3.31 to $3.315. On December 10, 2025, the officer similarly exercised options for 645 shares at $0.06 per share and sold 645 shares at $3.35 per share.
The filing shows these transactions as direct ownership and notes that the related stock options, which carry an exercise price of $0.06 and expire on May 6, 2031, are fully vested. After the reported option exercises, the officer holds 370,441 stock options with the same exercise price.
Serina Therapeutics, Inc. reported transactions by its Chief Scientific Officer involving stock options and common stock in early December 2025. On December 2, 2025, the officer exercised stock options to acquire 1,500 shares of common stock at an exercise price of $0.06 per share, then sold 1,500 shares at a weighted average price of $3.9052 per share. On December 3, 2025, the officer exercised additional options for 5,000 shares at $0.06 per share and sold 5,000 shares at a weighted average price of $3.5246 per share.
After these transactions, the officer reported owning no shares of common stock directly, while continuing to hold 371,686 stock options with an exercise price of $0.06 per share, expiring on May 6, 2031. The weighted average sale prices reflect multiple trades within price ranges disclosed in the footnotes, and the options involved in these sales are fully vested.
Serina Therapeutics, Inc. (SER) reported an insider equity transaction by its Chief Scientific Officer on 11/25/2025. The officer exercised a stock option to buy 5,965 shares of common stock at an exercise price of $0.06 per share, then sold 5,965 shares of common stock at a weighted average price of $3.9001 per share, with individual sale prices ranging from $3.90 to $3.91.
After these transactions, the officer directly beneficially owned 5,965 shares of common stock and held 378,186 stock options directly. The filing notes that the reported sale price is a weighted average and the officer will provide details of the individual trade prices upon request.
Serina Therapeutics, Inc. reported an insider equity transaction by its Chief Scientific Officer. On 11/24/2025, the officer exercised a stock option to acquire 535 shares of common stock at an exercise price of $0.06 per share and then sold 535 shares of common stock on the same date.
The sale price reported for these shares is a weighted average of $3.935 per share, with individual sales executed at prices ranging from $3.917 to $3.98. Following these transactions, the reporting person holds 384,151 derivative securities in the form of stock options that remain beneficially owned and are fully vested.
Serina Therapeutics, Inc. officer reports option exercise and share sale. The company’s Chief Scientific Officer exercised stock options for 6,500 shares of common stock at an exercise price of $0.06 per share on 11/18/2025. On the same date, 6,500 shares of common stock were sold in an open market transaction at a weighted average price of $3.7541 per share, leaving 0 shares of common stock directly owned after the transaction. The filing also shows that 384,686 stock options with a $0.06 exercise price remained beneficially owned following the reported transactions, and these options are fully vested with an expiration date of 05/06/2031.
Serina Therapeutics (SER) insider transaction: The Chief Scientific Officer exercised stock options for 6,500 shares at $0.06 on 11/10/2025 and sold 6,500 shares of common stock at a weighted average price of $4.10. The filing notes sales occurred in multiple trades between $4.30 and $4.00. Following these transactions, common stock beneficial ownership was 0 shares.
The option exercised was a stock option (right to buy) fully vested, with an expiration date of 05/06/2031. Derivative securities beneficially owned after the reported transactions totaled 391,186 options.
Serina Therapeutics (SER) reported a director stock option grant. On 11/07/2025, the reporting person received stock options for 10,000 shares at a $3.91 exercise price. The options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to continued service. The options expire on 11/07/2035. Following the grant, 10,000 derivative securities were beneficially owned, held directly. The transaction was coded “A” for award/grant.
Serina Therapeutics (SER) reported a director equity grant. On 11/07/2025, a stock option (right to buy) for 10,000 shares was awarded at an exercise price of $3.91 per share, coded A for grant. The option expires on 11/07/2035 and was recorded as Direct (D) ownership with 10,000 derivative securities beneficially owned after the transaction.
The options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to the director’s continued service.
Serina Therapeutics (SER) reported a director equity award. On 11/07/2025, the director received stock options for 10,000 shares at an exercise price of $3.91, expiring on 11/07/2035. The options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to continued service. Following the award, the reporting person beneficially owned 10,000 derivative securities directly.
Serina Therapeutics (SER) reported a routine insider equity award. A director received a stock option grant for 10,000 shares on 11/07/2025 with an exercise price of $3.91 and an expiration date of 11/07/2035.
The options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, conditioned on continued service. The filing lists the derivative security as directly owned and records the post‑transaction derivative balance at 10,000.
Serina Therapeutics (SER) reported an insider equity award. A director received a grant of 10,000 stock options on 11/07/2025 with an exercise price of $3.91 per share.
The options expire on 11/07/2035 and will vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, contingent on continued service. Following the grant, the reporting person beneficially owns 10,000 derivative securities, held Direct (D). The grant price for the derivative security was listed as $0.
Serina Therapeutics (SER) reported an insider transaction by its Chief Scientific Officer. On 11/05/2025, the officer exercised stock options for 3,398 shares at $0.06 per share and sold 3,398 common shares at a $4.24 weighted average price, with individual sale prices ranging from $4.30 to $4.225.
Following the transactions, the non-derivative common stock balance reported was 0 shares direct. Derivative holdings reported included 397,686 stock options. The exercised option series listed an expiration of 05/06/2031.
Serina Therapeutics (SER): Form 4 insider activity. The Chief Scientific Officer exercised stock options for 3,102 shares at $0.06 on 11/04/2025 and sold 3,102 common shares at a weighted average price of $4.3953 the same day. Following these transactions, common stock beneficially owned was 0 shares direct. The filing notes the sale was executed in multiple trades between $4.65 and $4.35. The reporting person continues to hold 401,084 stock options, which are fully vested, expiring on 05/06/2031.
Serina Therapeutics (SER) reported an insider transaction by its Chief Scientific Officer. On 10/28/2025, the officer exercised 5,551 stock options at $0.06 per share and sold 5,551 shares at a weighted average price of $4.9615.
After these transactions, directly held common stock was 0 shares. The filing lists 404,186 derivative securities (stock options) beneficially owned following the transactions. The reported options are fully vested and carry an expiration date of 05/06/2031.
Serina Therapeutics (SER) disclosed an insider transaction by its Chief Scientific Officer. On 10/27/2025, the officer exercised 949 stock options at $0.06 and sold 949 common shares at a weighted average price of $5.1857, with sales ranging from $5.25 to $5.10. After these transactions, 0 common shares were beneficially owned directly, and 409,737 stock options remained outstanding and are fully vested.
Serina Therapeutics (SER) Chief Scientific Officer Randall Moreadith exercised stock options for 6,500 shares at $0.06 and sold 6,500 shares at a weighted average price of $4.9672 on 10/20/2025.
The sale occurred in multiple transactions between $5.02 and $4.88. Following the transactions, the Form 4 reports 0 shares of common stock directly owned and 410,686 derivative securities (stock options) beneficially owned. The exercised option was fully vested and carried a $0.06 exercise price with an expiration date of 05/06/2031.